Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Waldenstrom's Macroglobulinemia
NCT00811733Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in Waldenström macroglobulinemia (WM), sponsored by GSK. Started Mar 2009; status: completed.
02
Drugs
ofatumumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00811733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811733.